Management of Small Renal Masses:
The Role of Percutaneous Biopsy
Part 1: Introduction
Part 2: Management of SRM Role of Percutaneous Biopsy: Biopsy can be used to Dictate
Management Options
Part 3: Renal Mass Biopsy Does Not Influence Treatment Decisions
Part 4: Effect of Renal Cancer Size on Metastasis and Mortality
Release Date: January 21, 2009
Expiration Date: January 21, 2010
 |
||
|
How to Obtain AMA PRA
|
|
 |
||
Estimated Time of Completion: 45 minutes
Description
Incidental renal masses are a common phenomenon that are increasing in incidence given the wide spread use of abdominal imaging. Historically, renal mass biopsy has not been pursued because of concerns about safety and spread of cancer. As these fears have largely abated and given new therapeutic options, an increase role for biopsy of the small renal mass has emerged. This webcast will put this procedure in its proper context and focus on the current view of the role of percutaneous biopsy. Importantly, the limitations of the information obtained from a renal biopsy, including histology, grade and other features will be discussed in regards to choosing the most appropriate management strategy cooperating with a small renal mass.
Objectives
At the conclusion of this activity, the participant will be able to:
- Identify the current and future role of percutaneous biopsy of incidental renal masses on treatment decisions.
- Review treatment options for patients that present with an incidental renal mass.
- Interpret the limitations of information obtained from a renal biopsy.
Target Audience
This activity is directed to medical oncologists and urologists.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director(s)
Brian Rini, MD |
Planning Committee
Thomas Hutson, D.O., PharmD. |
Christopher Wood, M.D., FACS |
Faculty
Inderbir Gill, MD |
Michael Jewett, MD |
Samir Taneja, MD |
Faculty Disclosure
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty have indicated that they may have a relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest:
| Thomas Hutson, MD | |||
| Consulting; Teaching & Speaking; Membership on advisory committee or
review panels: |
Bayer; Pfizer; Wyeth | ||
| Independent Contractor: | Bayer; GSK; Pfizer; Wyeth | ||
| Brian Rini, MD | |||
| Consulting; Membership on advisory committee or review panels: | Genentech; Novartis; Pfizer; Wyeth | ||
| Christopher Wood, MD | |||
| Consulting; Teaching & Speaking: | Ethicon; Pfizer | ||
The following faculty has indicated he/she has no relationship which, in the context of their presentation(s), could be perceived as a potential conflict of interest:
Inderbir Gill, M.D.
Michael A.S. Jewett, M.D.
Samir Taneja, M.D.
This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education and UNITECH Communications®.
